Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 10, 2019
Document And Entity Information
Entity Registrant Name	IMAC Holdings, Inc.
Entity Central Index Key	0001729944
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		8,316,797
Trading Symbol	IMAC
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 3,065,553	$ 194,316
Accounts receivable, net	665,080	303,630
Due from related parties
Other assets	400,959	170,163
Total current assets	4,131,592	668,109
Property and equipment, net	3,221,183	3,333,638
Other assets:
Goodwill	2,042,125	2,042,125
Intangible assets, net	4,126,748	4,257,434
Deferred IPO Costs		335,318
Security deposits	441,473	438,163
Right of use asset	4,027,124
Total other assets	10,637,470	7,073,040
Total assets	17,990,245	11,074,787
Current liabilities:
Accounts payable and accrued expenses	1,548,220	1,261,582
Acquisition liabilities	10,000	7,259,208
Patient deposits	939,772	454,380
Due to related parties
Notes payable, current portion	3,032,686	4,459,302
Capital lease obligation, current portion	16,920	16,740
Line of credit	229,961	379,961
Operating lease	724,587
Total current liabilities	6,502,146	13,831,173
Long-term liabilities:
Notes payable, net of current portion	276,854	317,291
Capital Lease Obligation, net of current portion	79,740	84,038
Deferred Rent	185,022	197,991
Lease Incentive Obligation	549,695	576,454
Operating lease, net of current portion	3,310,403
Total liabilities	10,903,860	15,006,947
Stockholders' equity (deficit):
Preferred stock - $0.001 par value, 5,000,000 authorized, nil issued and outstanding
Common stock; $0.001 par value, 30,000,000 authorized, 7,252,923 and 4,533,623 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	7,253	4,534
Additional paid-in capital	14,280,204	1,233,966
Accumulated deficit	(5,144,009)	(3,544,820)
Non-controlling interest	(2,057,063)	(1,625,840)
Total stockholders' equity (deficit)	7,086,385	(3,932,160)
Total liabilities and stockholders' equity (deficit)	$ 17,990,245	$ 11,074,787

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	7,252,923	4,533,623
Common stock, shares outstanding	7,252,923	4,533,623

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total patient revenue, net	$ 2,769,828	$ 234,253
Total revenue	2,769,828	267,853
Operating expenses:
Patient expenses	436,129	37,134
Salaries and benefits	2,064,623	446,796
Share-based compensation	3,749	3,749
Advertising and marketing	347,016	93,178
General and administrative	977,369	239,692
Depreciation and amortization	285,567	31,268
Total operating expenses	4,114,453	851,817
Operating loss	(1,344,626)	(583,964)
Other income (expense):
Interest income		3,312
Other (loss)	(15,955)
Beneficial conversion interest expense	(639,159)
Interest expense	(30,671)	(23,552)
Total other (expenses)	(685,785)	(20,240)
Loss before equity in (loss) of non-consolidated affiliate	(2,030,410)	(604,204)
Equity in (loss) of non-consolidated affiliate		(85,651)
Net loss before income taxes	(2,030,410)	(689,855)
Income taxes
Net loss	(2,030,410)	(689,855)
Net loss attributable to the non-controlling interest	431,223	285,191
Net loss attributable to IMAC Holdings, Inc.	$ (1,599,187)	$ (404,664)
Net loss per share attributable to common stockholders Basic and diluted	$ (0.27)	$ (0.09)
Weighted average common shares outstanding Basic and diluted	5,919,856	4,533,623
Patient Revenues [Member]
Total patient revenue, net	$ 7,289,022	$ 532,872
Contractual Adjustments [Member]
Total patient revenue, net	(4,519,194)	(298,619)
Management Fees [Member]
Total revenue		$ 33,600

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - 3 months ended Mar. 31, 2019 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Noncontrolling Interest [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 4,534	$ 1,233,966	$ (1,625,840)	$ (3,544,820)	$ (3,932,160)
Balance, shares at Dec. 31, 2018	4,533,623
Common stock issued for initial public offering proceeds, net of related fees	$ 850	3,503,314			3,504,164
Common stock issued for initial public offering proceeds, net of related fees, shares	850,000
Issuance of common stock in connection with convertible notes	$ 449	2,245,636			2,246,085
Issuance of common stock in connection with convertible notes, shares	449,217
Issuance of common stock in connection with acquisitions	$ 1,410	7,247,798			7,249,208
Issuance of common stock in connection with acquisitions, shares	1,410,183
Exercise of warrants	$ 10	49,490			49,500
Exercise of warrants, shares	9,900
Net loss			(431,223)	(1,599,187)	(2,030,410)
Balance at Mar. 31, 2019	$ 7,253	$ 14,280,204	$ (2,057,063)	$ (5,144,007)	$ 7,086,385
Balance, shares at Mar. 31, 2019	7,252,923

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (2,030,410)	$ (689,855)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	285,567	31,268
Beneficial conversion interest expense	639,159
Deferred rent	(12,969)	2,408
Equity in loss of non-consolidated affiliate		85,651
(Increase) decrease in operating assets:
Accounts receivable, net	(361,450)	(503)
Due from related parties
Other assets	(230,796)	(118,410)
Security deposits	(3,310)
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	361,428	136,685
Patient deposits	485,392	(22,249)
Lease incentive obligation	(26,759)	(1,536)
Net cash (used in) operating activities	(894,149)	(576,541)
Cash flows from investing activities:
Purchase of property and equipment	(42,426)	(1,191,620)
Investment in and advances go IMAC St Louis LLC		(124,106)
Net cash (used in) investing activities	(42,426)	(1,315,726)
Cash flows from financing activities:
Proceeds from initial public offering	3,839,482
Proceeds from warrants exercised	49,500
Proceeds from notes payable	100,000	2,262,500
Payments on notes payable	(27,053)	(20,590)
Proceeds from line of credit		75,000
Payments on line of credit	(150,000)
Payments on capital lease obligation	(4,118)	(1,922)
Net cash provided by financing activities	3,807,811	2,314,988
Net increase in cash	2,871,237	422,721
Cash, beginning of period	194,316	127,788
Cash, end of period	3,065,553	550,509
Supplemental cash flow information:
Interest paid	$ 30,671	$ 23,552

Description of Business

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Description of Business

Note 1 – Description of Business

IMAC Holdings, Inc. and its affiliates (collectively, the “Company”) provide orthopedic therapies through its chain of IMAC Regeneration Centers. Through its consolidated and equity owned entities, its outpatient medical clinics provide conservative, non-invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. The Company had opened two (2) medical clinics located in Tennessee and opened or acquired through management service agreements nine (9) medical clinics located in Kentucky and Missouri at March 31, 2019. The Company has partnered with several well-known sports stars such as Ozzie Davis and David Price in opening its medical clinics, with a focus around treating sports injuries.

Effective June 1, 2018, the Company converted from IMAC Holdings, LLC a Kentucky limited liability company to IMAC Holdings, Inc. a Delaware corporation, followed by a reverse stock split in February 2019. These accounting changes have been given retrospective treatment in the condensed consolidated financial statements.

During February 2019, the Company completed an initial public offering (“IPO”) of securities. See Note 13.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”). In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Interim results are not necessarily indicative of results for a full year. Therefore, the interim unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements contained in the Company’s Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements include the accounts of IMAC Holdings, Inc. (“IMAC Holdings”) and the following entities which are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity: IMAC Management Services, LLC (“IMAC Management”), IMAC Regeneration Management, LLC (“IMAC Texas”) and IMAC Regeneration Management of Nashville, LLC (“IMAC Nashville”); the following entity which is consolidated with IMAC Regeneration Management of Nashville, LLC due to control by contract: IMAC Regeneration Center of Nashville, PC (“IMAC Nashville PC”); and the following entity which prior to June 1, 2018 was held as a minority interest, IMAC Regeneration Center of St. Louis, LLC (“IMAC St. Louis”).

In June 2018, the Company consummated certain transactions resulting in the acquisition of the outstanding equity interests in IMAC St. Louis and Clinic Management Associates of KY, LLC (“CMA of KY”), an entity which is consolidated with Integrated Medical and Chiropractic Regeneration Center, PSC (“IMAC Kentucky”) due to control by contract. These entities are included in the consolidated financial statements from the date of acquisition.

In August 2018, the Company acquired 100% of Advantage Hand Therapy and Orthopedic Rehabilitation, LLC (“Advantage Therapy”) and 70% of BioFirma LLC (“BioFirma”). Both companies are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity.

All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the condensed consolidated financial statements are prepared. On an ongoing basis, the Company evaluates its estimates, including those related to insurance adjustments and provisions for doubtful accounts. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could materially differ from those estimates.

Revenue Recognition

The Company’s patient service revenue is derived from non-surgical procedures performed at our outpatient medical clinics and patient visits to physicians. The fees for such services are billed either to the patient or a third- party payer, including Medicare. We recognize patient service revenue, net of contractual allowances, which we estimate based on the historical trend of our cash collections and contractual write-offs.

Other management service fees are derived from management services where the Company provides billings and collections support to the clinics and where management services are provided based on state specific regulations known as the corporate practice of medicine (“CPM”). Under the CPM, a business corporation is precluded from practicing medicine or employing a physician to provide professional medical services. In these circumstances, the Company provides all administrative support to the physician-owned PC through an LLC. The PC is consolidated due to control by contract (an “MSA” – Management Services Agreement). The fees we derive from these management arrangements are either based on a predetermined percentage of the revenue of each clinic or a percentage mark up on the costs of the LLC. We recognize other management service revenue in the period in which services are rendered. These revenues are earned by IMAC Nashville and IMAC Management and are eliminated in consolidation to the extent owned.

Patient Deposits

Patient deposits are derived from patient payments in advance of services delivered. Our service lines include traditional and regenerative medicine. Regenerative medicine procedures are not paid by insurance carriers; therefore, the Company typically requires up-front payment from the patient for regenerative services and any co-pays and deductibles as required by the patient specific insurance carrier. For some patients, credit is provided through an outside vendor. In this case, the Company is paid from the credit card company and the risk is transferred to the credit card company for collection from the patient. These funds are accounted for as patient deposits until the procedures are performed at which point the patient deposit is recognized as patient service revenue.

Fair Value of Financial Instruments

The carrying amount of accounts receivable, accounts payable and acquisition liabilities approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents.

Accounts Receivable

Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s condensed consolidated financial statements are recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write- offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payer, size of claim and estimated collection percentage for each patient account. The operating systems used to manage the Company’s patient accounts provide for an aging schedule in 30-day increments, by payer, physician and patient. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.

Allowance for Doubtful Accounts, Contractual and Other Discounts

Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.

Intangible Assets

The Company capitalizes the fair value of intangible assets acquired in business combinations. The Company performs valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination and allocates the purchase price of each acquired business to its respective net tangible and intangible assets. Acquired intangible assets include trade names, non-compete agreements, customer relationships and contractual agreements.

Goodwill

The Company tests goodwill for impairment on an annual basis, or when events or circumstances indicate the fair value of a reporting unit is below its carrying value.

Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the years presented.

Long-Lived Assets

Long-lived assets such as property and equipment and intangible assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long lived assets for the years presented.

Advertising and Marketing

The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred. Advertising and marketing expense was $347,016 and $93,178 for the three months ended March 31, 2019 and 2018, respectively (unaudited).

Net Loss Per Share

Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.

Income Taxes

IMAC Management, IMAC Texas, and IMAC Nashville are limited liability companies and are taxed as partnerships. IMAC Holdings was taxed as a partnership through May 31, 2018. As a result, income tax liabilities are passed through to the individual members. Accordingly, no provision for income taxes were reflected in the condensed consolidated financial statements for periods prior to May 31, 2018 at which time IMAC Holdings converted from a limited liability company to a Delaware corporation.

The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. For the three months ended March 31, 2019 and 2018, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2016 are open and subject to examination by the taxing authorities.

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. This update simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. Under this updated standard, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity also should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if any. This guidance is effective prospectively and is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. The Company does not expect the adoption of this guidance to have a material impact on our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases” which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The ASU was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We recognized a right of use asset and related obligation on our condensed consolidated financial statements.

Capital Requirements, Liquidity and Going Concern Considerations

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Capital Requirements, Liquidity and Going Concern Considerations

Note 3 – Capital Requirements, Liquidity and Going Concern Considerations

The Company’s condensed consolidated financial statements are prepared in accordance with GAAP including the assumption of a going concern basis, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying condensed consolidated financial statements, the Company has sustained substantial losses from operations since inception and has a deficiency in working capital of approximately $13.1 million and $2.4 million at December 31, 2018 and March 31, 2019, respectively. The Company had a net loss of approximately $2.0 million and $0.7 million at March 31, 2019 and 2018, respectively, and used cash of $0.8 million and $0.6 million at March 31, 2019 and 2018, respectively, in its operations. The Company expects to continue to incur significant expenditures to develop and expand its owned and managed outpatient medical clinics.

Management recognizes that the Company must obtain additional resources to successfully integrate its acquired and managed clinics and implement its business plans. Through December 31, 2018, the Company had received funding in the form of indebtedness. Subsequent to December 31, 2018, the Company completed an initial public offering of 850,000 units, in which the Company received aggregate gross proceeds of approximately $4.3 million and extinguished liabilities of approximately $7.2 million. Management plans to continue to raise funds and/or refinance the Company’s indebtedness to support its operations in 2019 and beyond. However, no assurances can be given that the Company will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Concentration of Credit Risks

3 Months Ended

Mar. 31, 2019

Risks and Uncertainties [Abstract]

Concentration of Credit Risks

Note 4 – Concentration of Credit Risks

Cash

The Company maintains its cash in accounts at financial institutions, which may, at times, exceed federally-insured limits of $250,000. As of March 31, 2019 and December 31, 2018, the Company had $2,536,458 and $0, respectively, of cash in excess of federally insured limits. The Company has not experienced any losses on such accounts and does not feel it is exposed to any significant risk with respect to cash.

Revenue and Accounts Receivable

The Company had the following revenue and accounts receivable concentrations:

	March 31,
	2019						2018
	% of Revenue			% of Accounts Receivable			% of Revenue			% of Accounts Receivable
				(unaudited)
Patient payment		54	%		54	%		64	%		64	%
Medicare payment		22	%		22	%		13	%		13	%
Insurance payment		24	%		24	%		23	%		23	%
Total		100	%		100	%		100	%		100	%

Accounts Receivable

3 Months Ended

Mar. 31, 2019

Receivables [Abstract]

Accounts Receivable

Note 5 – Accounts Receivable

Accounts receivable consisted of the following at March 31, 2019 and December 31, 2018:

	March 31, 2019			December 31, 2018
	(unaudited)
Gross accounts receivable	$	727,976		$	314,185
Less: allowance for doubtful accounts
and contractual adjustments		(62,896	)		(10,555	)
Accounts receivable, net	$	665,080		$	303,630

Business Acquisitions

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Business Acquisitions

Note 6 – Business Acquisitions

During June 2018, the Company acquired CMA of Kentucky and IMAC St. Louis for aggregate consideration of approximately $6.1 million to be paid in equity. The operating results of these two companies have been included in the Company’s consolidated financial statements from their dates of acquisition. The Company accounted for the transactions as business combinations, and has allocated the purchase consideration to the net assets acquired based on estimated fair values.

In addition, during June 2018, the Company acquired the non-controlling interest held in its majority-owned subsidiary IMAC Nashville for $300,000 to be paid in equity.

During August 2018, the Company acquired Advantage Therapy and BioFirma for aggregate consideration of approximately $900,000 to be paid in cash and equity. The operating results of these two companies have been included in the Company’s consolidated financial statements from their dates of acquisition. The Company accounted for the transactions as business combinations, and has allocated the purchase consideration to the net assets acquired based on estimated fair values.

IMAC Kentucky

On June 29, 2018, IMAC Management completed a merger of CMA of KY into IMAC Management. Pursuant to this merger, IMAC Management has a long-term MSA to provide exclusive comprehensive management and related administrative services to IMAC Kentucky, an entity engaged in the practice of medicine through physicians and nurse practitioners. Under the IMAC Kentucky MSA, the Company receives service fees based on the cost of the services provided, plus a specified markup percentage, and a discretionary annual bonus.

The Company has included the consolidated financial results of IMAC Kentucky in its consolidated financial statements from the date of acquisition.

IMAC St. Louis

On June 1, 2018, the Company acquired the remaining 64% membership interest in IMAC St. Louis not already owned by it pursuant to a Unit Purchase Agreement, increasing the Company’s ownership to 100%. IMAC St. Louis operates two (2) Ozzie Smith Centers in Missouri. Pursuant to the terms of the Unit Purchase Agreement, the Company agreed to pay the current owners, upon the closing of the Company’s initial public offering, an amount equal to 1.05 times the total collections from payments at the IMAC St. Louis centers on account of regeneration-related services and associated products from the period from June 1, 2017 to May 31, 2018, or $1,490,632. The purchase consideration will be payable in the form of shares of our common stock based on the price per share of the Company’s common stock in the Company’s initial public offering. See Note 13.

The Company has included the financial results of IMAC St. Louis in its consolidated financial statements from June 1, 2018, the date of acquisition.

IMAC Nashville

Also on June 1, 2018, the Company acquired the remaining 25% of the outstanding units of the limited liability company membership interests not already owned by the Company in IMAC Nashville for $300,000 which was paid in shares of our common stock based on the price per share of the Company’s common stock in the Company’s initial public offering. See Note 13.

Advantage Therapy

On August 1, 2018, the Company entered into an agreement to purchase all outstanding membership units of Advantage Therapy. The purchase price for the interests was equal to the dollar amount represented by 0.7 times the total collections from payments for service in Advantage Therapy’s account from June 1, 2017 to May 31, 2018, or approximately $892,000, of which $870,000 and $22,000 and were payable in equity and cash, respectively. See Note 13.

The Company has included the financial results of Advantage Therapy in its consolidated financial statements from August 1, 2018, the date of acquisition.

BioFirma

On August 1, 2018, the Company entered into an agreement to purchase 70% of all outstanding membership units of BioFirma LLC. The purchase price for the interests was $1,000 paid in cash. BioFirma owns a trademark on NeoCyte, an umbilical cord-derived mononuclear cell product following FDA cGMP regulations. The Company has committed to further research and development of NeoCyte and other regenerative medicine products.

The Company has included the financial results of BioFirma in its consolidated financial statements from August 1, 2018, the date of acquisition.

The following table summarizes the fair value of consideration paid and the allocation of purchase price to the fair value of net assets acquired for the business acquisitions:

	IMAC Kentucky			IMAC St. Louis		Advantage Therapy			BioFirma
Property & equipment	$	607,257		$	-	$	18,647		$	-
Intangible Assets		4,224,113			264,000		37,000			1,429
Goodwill		-			1,327,507		713,189			-
Other assets		5,521			-		255,018			-
Current liabilities		(119,902	)		-		(50,948	)		-
Noncurrent liabilities		(118,413	)		-		(79,975	)		-
Non-controlling interest		-			-		-			(429	)
	$	4,598,576		$	1,591,507	$	892,931		$	1,000

Property and Equipment

3 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 7 – Property and Equipment

The Company’s property and equipment consisted of the following:

	Estimated	March 31,			December 31,
	Useful Life in Years	2019			2018

Land and Building	40	$	1,175,000		$	1,175,000
Leasehold improvements	Shorter of asset or lease term		1,614,778			1,427,828
Equipment	1.5 - 7		1,557,646			1,180,093
Total property and equipment			4,347,424			3,782,921
Less: accumulated depreciation			(1,126,241	)		(449,283	)
Total property and equipment, net		$	3,221,183		$	3,333,638

In March 2018, the Company purchased real estate in Lexington, Kentucky for the development of an IMAC facility for approximately $1.2 million. The Company funded the purchase with a note payable. See Note 11.

Depreciation was $154,881 and $31,268 for the three months ended March 31, 2019 and 2018, respectively.

Intangibles Assets and Goodwill

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles Assets and Goodwill

Note 8 – Intangibles Assets and Goodwill

The Company’s intangible assets that were acquired in connection with the business acquisition transactions (Note 6) during 2018 were as follows:

		December 31, 2018
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreement	10 years	$	4,224,113	$	(211,206	)	$	4,012,907
Non-compete agreements			301,000		(56,473	)		244,527
Definite lived assets	3 years		4,525,113		(267,679	)		4,257,434
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(267,679	)	$	6,299,559

		March 31, 2019

	Estimated				Accumulated
	Useful Life		Cost		Amortization			Net

Intangible assets:
Management service agreement	10 years	$	4,224,113	$	(316,808	)	$	3,907,305
Non-compete agreements			301,000		(81,557	)		219,443
Definite lived assets	3 years		4,525,113		(398,365	)		4,126,748
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(398,365	)	$	6,168,873

The Company’s estimated future amortization of intangible assets was as follows:

Years Ending December 31,

2019 (nine months)	$	392,058
2020		522,744
2021		466,273
2022		422,411
2023		422,411
Thereafter		1,900,851
	$	4,126,748

Operating Leases

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Operating Leases

Note 9 – Operating Leases

Adoption of ASC Topic 842, Leases

On January 1, 2019, the Company adopted Topic 842 using the modified retrospective method applied to leases that were in place as of January 1, 2019. Results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Topic 840. The Company’s leases consists of operating leases that relate to real estate rental agreements. All of the value of the Company’s lease portfolio relates to a real estate lease agreements that were entered into starting March 2017.

Practical Expedients and Elections

The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. We also elected the short-term lease recognition exemption for all leases that qualify.

Discount Rate Applied to Property Operating Lease

To determine the present value of minimum future lease payments for operating leases at January 1, 2019, the Company was required to estimate a rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment (the “incremental borrowing rate” or “IBR”).

The Company determined the appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the ten year mortgage interest rate.

Right of Use Assets

Right of use assets are included in the unaudited condensed consolidated Balance Sheet as follows:

Non-current assets
Right of use assets, net of amortization	$	4,027,124

Total operating lease cost

Individual components of the total lease cost incurred by the Company is as follows:

	Three Months Ended March 31, 2019

Operating lease expense	$	208,912

Minimum rental payments under operating leases are recognized on a straight light basis over the term of the lease.

Maturity of operating leases

The amount of future minimum lease payments under operating are as follows:

	Operating Lease

Undiscounted future minimum lease payments:
2019 (remainder of year)	$	637,733
2020		794,101
2021		643,082
2022		641,947
2023		611,158
Thereafter		1,100,783
Total		4,428,803
Amount representing imputed interest		(393,813	)
Total operating lease liability		4,034,990
Current portion of operating lease liability		(724,587	)
Operating lease liability, non-current	$	3,310,403

Lines of Credit

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Lines of Credit

Note 10 – Lines of Credit

IMAC Nashville had a $150,000 line of credit with a financial institution that matured on October 15, 2018. The line bore interest at 6.50% per annum. The line is secured by substantially all of the Company’s assets and personally guaranteed by the members. The LOC had a $150,000 balance at December 31, 2018. The line of credit was repaid in February 2019.

IMAC Kentucky has a $150,000 line of credit with a financial institution that matured on August 1, 2018. The line bears interest at 4.25% per annum. The line was secured by substantially all of the IMAC Kentucky’s assets and personally guaranteed by the members. The LOC had a $150,000 balance at December 31, 2018 and $150,000 (unaudited) at March 31, 2019.

Advantage Therapy has a $100,000 line of credit with a financial institution that matures on November 20, 2020. The line bears interest at a variable rate which is currently 6.0% per annum. The line is secured by substantially all of IMAC Holding’s assets. The LOC had a $79,975 balance at December 31, 2018 and $79,961 at March 31, 2019.

Notes Payable

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Notes Payable

Note 11-Notes Payable

	March 31, 2019			December 31, 2018

Note payable to The Edward S. Bredniak Trust in the amount of up to $2,000,000. An existing note payable with this entity in the amount of $379,676 has been combined into the new note payable. The note carries an interest rate of 10% per annum and all outstanding balances are due and payable December 31, 2019.	$	1,684,426		$	1,584,426

Note payable to a financial institution in the amount of $200,000 dated November 15, 2017. The note requires 66 consecutive monthly installments of $2,652 including principal and interest at 5%, with a balloon payment of $60,000 which was paid on June 15, 2018. The note matures on May 15, 2023, and is secured by the personal guarantees of the Company’s management.		119,259			125,670

Convertible notes issued to various investors, which accrued interest at 4%, and converted to common stock in connection with the closing of the Company’s initial public offering. See Note 13. The notes were convertible to equity at or prior to maturity at a 20% discount to the per share price of a sale of equity securities. At the time of issuance of the convertible notes, the Company was unable to calculate the amount of a beneficial conversion (“BCF”) and related discount to be recorded until the occurrence of a qualified financing by the Company. Upon the closing of the Company’s initial public offering, the Company recognized the BCF and related interest charge associated with the discount, and the BCF has been classified as a liability to the extent it met the conditions for derivative treatment at the time of recognition.		-			1,540,000

$1.2 million mortgage loan with a financial institution. The loan agreement is for 6-months and carries an interest rate 3.35%. The loan matured in 2018 and was extended to 2019. It is currently interest only and is now on a month to month basis.		1,232,500			1,232,500

Note payable to a financial institution in the amount of $131,400 dated August 1, 2016. The note requires 120 monthly installments of $1,394 including principal and interest at 5%. The note matures on July 1, 2026 and is secured by a letter of credit.		102,498			105,374

Note payable to a financial institution in the amount of $200,000 dated May 4, 2016. The note requires 60 monthly installments of $3,881 including principal and interest at 4.25%. The note matures on May 4, 2021 and is secured by the equipment and personal guarantees of the Company’s management.		96,232			106,778

Note payable to an employee in the amount of $101,906 dated March 8, 2017. The note requires 5 annual installments of $23,350 including principal and interest at 5%. The note matures on December 31, 2021 and is unsecured.		60,000			60,000

Note payable to a financial institution in the amount of $133,555 dated September 17, 2014. The note requires 60 monthly installments of $2,475 including principal and interest at 4.25%. The note matures on September 17, 2019.		14,625			21,845
		3,309,540			4,776,593
Less: current portion:		(3,032,686	)		(4,459,302	)
	$	276,854		$	317,291

Principal maturities of the Company’s notes payable are as follows:

Years Ending December 31,	Amount

2019 (nine months)	$	3,012,357
2020		104,435
2021		80,968
2022		43,935
2023		27,404
Thereafter		40,441
Total	$	3,309,540

Related Party Transactions

3 Months Ended

Mar. 31, 2019

Related Party Transactions

Note 12 – Related Party Transactions

From time to time, the Company advances funds to, and receives funds from, entities with common ownership. At December 31, 2018 and March 31, 2019, the amount owed to related parties was $0.

The Company contracted with SpeakLife to provide staff training and patient advocacy services for $99,000 per year. SpeakLife is owned by the Company’s Executive Vice President of Clinical Operations. This contract was terminated on June 30, 2018.

The Company contracted with UCI to provide marketing services to chiropractic practitioners and sources opportunities to expand chiropractic practices into regenerative medicine for $144,000 per year. UCI is owned by the spouse of the Company’s Chief Operations Officer. This contract was terminated on June 30, 2018.

Shareholders' Equity

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Shareholders' Equity

Note 13 – Shareholders’ Equity

Prior to the Company’s conversion to a corporation, the Company had 400 member units authorized with 365 units issued and outstanding.

On June 1, 2018, the Company converted its 365 outstanding member units into 6,582,737 shares of common stock with a $0.001 par value pursuant to the Company’s conversion from a limited liability company to a corporation. The conversion has been given retrospective treatment.

On February 12, 2019, the Company reverse split its 6,582,737 shares of common stock outstanding to 4,533,623 shares of common stock outstanding pursuant to an amendment of the Company’s certificate of incorporation. The reverse split has been given retrospective treatment.

During February 2019, the Company completed an initial public offering of securities and issued 850,000 shares of its common stock, along with 1,700,000 warrants to purchase common stock and an option to purchase 34,000 shares of common stock for gross proceeds of $4,356,815. The Company also issued 449,217 shares of common stock for the conversion of its 4% convertible notes and 1,410,183 shares to satisfy deferred acquisition consideration payable in connection with its 2018 business acquisitions.

Retirement Plan

3 Months Ended

Mar. 31, 2019

Retirement Benefits [Abstract]

Retirement Plan

Note 14 – Retirement Plan

The Company offers a 401(k) plan that covers eligible employees. The plan provides for voluntary salary deferrals for eligible employees. Additionally, the Company is required to make matching contributions of 50% of up to 6 % of total compensation for those employees making salary deferrals. The Company made contributions of $7,407 and $0 during the three months ended March 31, 2019 and 2018, respectively.

Income Taxes

3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 15 – Income Taxes

The Company’s provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows:

Deferred tax benefit at the federal statutory rate	21	%
Valuation allowance	-21	%
	0	%

At March 31, 2019, the Company has a net operating loss carryforward of approximately $3.7 million for federal and state purposes. This loss will be available to offset future taxable income. If not used, this carryforward will begin to expire in 2029. The deferred tax asset relating to the operating loss carryforward has been fully reserved at March 31, 2019. The principal differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 16 – Commitments and Contingencies

The Company is subject to extensive regulation, including health insurance regulations directed at ascertaining the appropriateness of reimbursement, preventing fraud and abuse and otherwise regulating reimbursement. To ensure compliance, various insurance providers often conduct audits and request patient records and other documents to support claims submitted by the Company for payment of services rendered to customers. In the event that an audit results in discrepancies in the records provided, insurance providers may be entitled to extrapolate the results of the audit to make overpayment demands based on a wider population of claims than those examined in the audit.

The Company is subject to threatened and asserted various legal proceedings in the ordinary course of business. The outcome of any legal proceeding is not within the Company’s complete control, it is often difficult to predict and is resolved over very long periods of time. Estimating probable losses associated with any legal proceedings or other loss contingencies are very complex and require the analysis of many factors including assumptions about potential actions by third parties. Loss contingencies are disclosed when there is at least a reasonable possibility that a loss has been incurred and are recorded as liabilities in the condensed consolidated financial statements when it is both (1) probable or known that a liability has been incurred and (2) the amount of the loss is reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability. If a loss contingency is not probable or cannot be reasonably estimated, a liability is not recorded in the financial statements.

In February 2019, the Company was made aware of a lawsuit involving a contract dispute with BioFirma. Management believes the ultimate resolution of this matter will not have a material impact on the Company’s financial condition or results of operations.

Subsequent Events

3 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

Note 17 – Subsequent Events

On April 1, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) for the acquisition of a practice management group that manages three clinics in the Chicago, Illinois area. On April 19, 2019, the Company entered into an Amendment to the Merger Agreement (the “Amendment”), effective as of April 19, 2019 at 12:05 a.m., with IMAC Management of Illinois, LLC, an Illinois limited liability company (“Merger Sub”), ISDI Holdings, Inc., an Illinois corporation (“ISDI Holdings I”), ISDI Holdings II, Inc., an Illinois corporation (“ISDI Holdings II”), PHR Holdings, Inc., an Illinois corporation (“PHR Holdings”), and Jason Hui, sole shareholder of each of ISDI Holdings II and PHR Holdings (the “Shareholder”), in order to amend the Agreement, executed on April 1, 2019 by and among the Company, Merger Sub, ISDI Holdings I and the Shareholder, to remove ISDI Holdings I as a party to the Agreement and, in its place, add ISDI Holdings II and PHR Holdings as parties to the Agreement and provide for the merger of each of ISDI Holdings II and PHR Holdings with and into Merger Sub (the “Merger”) on the terms and conditions set forth in the Agreement.

The Merger was completed on April 19, 2019, with Merger Sub remaining as the surviving entity. Pursuant to the Agreement, as amended by the Amendment, at the effective time of the Merger (the “Effective Time”), each of ISDI Holdings II and PHR Holdings’ issued and outstanding shares of common stock were cancelled and were converted automatically into the right of the Shareholder to receive 1,002,306 restricted shares of the Company’s common stock (the “Merger Consideration”). The Merger Consideration was issued to the Shareholder and a trust designated by the Shareholder on April 22, 2019. Representations were made to the Company regarding such share recipients’ knowledge and experience, ability to bear economic risk and investment purpose with respect to the restricted shares they received. The Merger Consideration was issued in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) of the Securities Act as a private offering. Such issuance did not involve a public offering, and was made without general solicitation or advertising.

In connection with the completion of the Merger, the Company also entered into an employment agreement with Dr. Jason Hui, which was effective as of April 19, 2019 and extends for a term expiring on March 31, 2022. Pursuant to his employment agreement, Dr. Hui has agreed to devote substantially all of his business time, attention and ability, to the Company as our Executive Vice President of Development. The employment agreement provides that Dr. Hui will receive a base salary at a rate of $350,000 per year through March 31, 2020, a base salary at a rate of $355,000 per year from April 1, 2020 through March 31, 2021 and a base salary at a rate of $360,000 per year for the period of April 1, 2021 through March 31, 2022.

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	*Principles of Consolidation* The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”). In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Interim results are not necessarily indicative of results for a full year. Therefore, the interim unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements contained in the Company’s Annual Report on Form 10-K. The accompanying condensed consolidated financial statements include the accounts of IMAC Holdings, Inc. (“IMAC Holdings”) and the following entities which are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity: IMAC Management Services, LLC (“IMAC Management”), IMAC Regeneration Management, LLC (“IMAC Texas”) and IMAC Regeneration Management of Nashville, LLC (“IMAC Nashville”); the following entity which is consolidated with IMAC Regeneration Management of Nashville, LLC due to control by contract: IMAC Regeneration Center of Nashville, PC (“IMAC Nashville PC”); and the following entity which prior to June 1, 2018 was held as a minority interest, IMAC Regeneration Center of St. Louis, LLC (“IMAC St. Louis”). In June 2018, the Company consummated certain transactions resulting in the acquisition of the outstanding equity interests in IMAC St. Louis and Clinic Management Associates of KY, LLC (“CMA of KY”), an entity which is consolidated with Integrated Medical and Chiropractic Regeneration Center, PSC (“IMAC Kentucky”) due to control by contract. These entities are included in the consolidated financial statements from the date of acquisition. In August 2018, the Company acquired 100% of Advantage Hand Therapy and Orthopedic Rehabilitation, LLC (“Advantage Therapy”) and 70% of BioFirma LLC (“BioFirma”). Both companies are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	*Use of Estimates* The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the condensed consolidated financial statements are prepared. On an ongoing basis, the Company evaluates its estimates, including those related to insurance adjustments and provisions for doubtful accounts. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could materially differ from those estimates.
Revenue Recognition	*Revenue Recognition* The Company’s patient service revenue is derived from non-surgical procedures performed at our outpatient medical clinics and patient visits to physicians. The fees for such services are billed either to the patient or a third- party payer, including Medicare. We recognize patient service revenue, net of contractual allowances, which we estimate based on the historical trend of our cash collections and contractual write-offs. Other management service fees are derived from management services where the Company provides billings and collections support to the clinics and where management services are provided based on state specific regulations known as the corporate practice of medicine (“CPM”). Under the CPM, a business corporation is precluded from practicing medicine or employing a physician to provide professional medical services. In these circumstances, the Company provides all administrative support to the physician-owned PC through an LLC. The PC is consolidated due to control by contract (an “MSA” – Management Services Agreement). The fees we derive from these management arrangements are either based on a predetermined percentage of the revenue of each clinic or a percentage mark up on the costs of the LLC. We recognize other management service revenue in the period in which services are rendered. These revenues are earned by IMAC Nashville and IMAC Management and are eliminated in consolidation to the extent owned.
Patient Deposits	*Patient Deposits* Patient deposits are derived from patient payments in advance of services delivered. Our service lines include traditional and regenerative medicine. Regenerative medicine procedures are not paid by insurance carriers; therefore, the Company typically requires up-front payment from the patient for regenerative services and any co-pays and deductibles as required by the patient specific insurance carrier. For some patients, credit is provided through an outside vendor. In this case, the Company is paid from the credit card company and the risk is transferred to the credit card company for collection from the patient. These funds are accounted for as patient deposits until the procedures are performed at which point the patient deposit is recognized as patient service revenue.
Fair Value of Financial Instruments	*Fair Value of Financial Instruments* The carrying amount of accounts receivable, accounts payable and acquisition liabilities approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.
Cash and Cash Equivalents	*Cash and Cash Equivalents* The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents.
Accounts Receivable	*Accounts Receivable* Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s condensed consolidated financial statements are recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients. The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write- offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payer, size of claim and estimated collection percentage for each patient account. The operating systems used to manage the Company’s patient accounts provide for an aging schedule in 30-day increments, by payer, physician and patient. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.
Allowance for Doubtful Accounts, Contractual and Other Discounts	*Allowance for Doubtful Accounts, Contractual and Other Discounts* Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.
Property and Equipment	*Property and Equipment* Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.
Intangible Assets	*Intangible Assets* The Company capitalizes the fair value of intangible assets acquired in business combinations. The Company performs valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination and allocates the purchase price of each acquired business to its respective net tangible and intangible assets. Acquired intangible assets include trade names, non-compete agreements, customer relationships and contractual agreements.
Goodwill	*Goodwill* The Company tests goodwill for impairment on an annual basis, or when events or circumstances indicate the fair value of a reporting unit is below its carrying value. Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the years presented.
Long-Lived Assets	*Long-Lived Assets* Long-lived assets such as property and equipment and intangible assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long lived assets for the years presented.
Advertising and Marketing	*Advertising and Marketing* The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred. Advertising and marketing expense was $347,016 and $93,178 for the three months ended March 31, 2019 and 2018, respectively (unaudited).
Net Loss Per Share	*Net Loss Per Share* Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.
Income Taxes	*Income Taxes* IMAC Management, IMAC Texas, and IMAC Nashville are limited liability companies and are taxed as partnerships. IMAC Holdings was taxed as a partnership through May 31, 2018. As a result, income tax liabilities are passed through to the individual members. Accordingly, no provision for income taxes were reflected in the condensed consolidated financial statements for periods prior to May 31, 2018 at which time IMAC Holdings converted from a limited liability company to a Delaware corporation. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. For the three months ended March 31, 2019 and 2018, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2016 are open and subject to examination by the taxing authorities.
Recent Accounting Pronouncements	*Recently Issued Accounting Pronouncements* In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. This update simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. Under this updated standard, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity also should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if any. This guidance is effective prospectively and is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. The Company does not expect the adoption of this guidance to have a material impact on our condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases” which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The ASU was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We recognized a right of use asset and related obligation on our condensed consolidated financial statements.

Concentration of Credit Risks (Tables)

3 Months Ended

Mar. 31, 2019

Risks and Uncertainties [Abstract]

Schedule of Concentration Risk

The Company had the following revenue and accounts receivable concentrations:

	March 31,
	2019						2018
	% of Revenue			% of Accounts Receivable			% of Revenue			% of Accounts Receivable
				(unaudited)
Patient payment		54	%		54	%		64	%		64	%
Medicare payment		22	%		22	%		13	%		13	%
Insurance payment		24	%		24	%		23	%		23	%
Total		100	%		100	%		100	%		100	%

Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2019

Receivables [Abstract]

Schedule of Accounts Receivable

Accounts receivable consisted of the following at March 31, 2019 and December 31, 2018:

	March 31, 2019			December 31, 2018
	(unaudited)
Gross accounts receivable	$	727,976		$	314,185
Less: allowance for doubtful accounts
and contractual adjustments		(62,896	)		(10,555	)
Accounts receivable, net	$	665,080		$	303,630

Business Acquisitions (Tables)

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Schedule of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of consideration paid and the allocation of purchase price to the fair value of net assets acquired for the business acquisitions:

	IMAC Kentucky			IMAC St. Louis		Advantage Therapy			BioFirma
Property & equipment	$	607,257		$	-	$	18,647		$	-
Intangible Assets		4,224,113			264,000		37,000			1,429
Goodwill		-			1,327,507		713,189			-
Other assets		5,521			-		255,018			-
Current liabilities		(119,902	)		-		(50,948	)		-
Noncurrent liabilities		(118,413	)		-		(79,975	)		-
Non-controlling interest		-			-		-			(429	)
	$	4,598,576		$	1,591,507	$	892,931		$	1,000

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The Company’s property and equipment consisted of the following:

	Estimated	March 31,			December 31,
	Useful Life in Years	2019			2018

Land and Building	40	$	1,175,000		$	1,175,000
Leasehold improvements	Shorter of asset or lease term		1,614,778			1,427,828
Equipment	1.5 - 7		1,557,646			1,180,093
Total property and equipment			4,347,424			3,782,921
Less: accumulated depreciation			(1,126,241	)		(449,283	)
Total property and equipment, net		$	3,221,183		$	3,333,638

Intangibles Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets that were acquired in connection with the business acquisition transactions (Note 6) during 2018 were as follows:

		December 31, 2018
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreement	10 years	$	4,224,113	$	(211,206	)	$	4,012,907
Non-compete agreements			301,000		(56,473	)		244,527
Definite lived assets	3 years		4,525,113		(267,679	)		4,257,434
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(267,679	)	$	6,299,559

		March 31, 2019

	Estimated				Accumulated
	Useful Life		Cost		Amortization			Net

Intangible assets:
Management service agreement	10 years	$	4,224,113	$	(316,808	)	$	3,907,305
Non-compete agreements			301,000		(81,557	)		219,443
Definite lived assets	3 years		4,525,113		(398,365	)		4,126,748
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(398,365	)	$	6,168,873

Schedule of Future Amortization of Intangible Assets

The Company’s estimated future amortization of intangible assets was as follows:

Years Ending December 31,

2019 (nine months)	$	392,058
2020		522,744
2021		466,273
2022		422,411
2023		422,411
Thereafter		1,900,851
	$	4,126,748

Operating Leases (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Schedule of Operating Lease Right of Use Assets

Right of use assets are included in the unaudited condensed consolidated Balance Sheet as follows:

Non-current assets
Right of use assets, net of amortization	$	4,027,124

Total operating lease cost

Schedule of Operating Lease Cost

Individual components of the total lease cost incurred by the Company is as follows:

	Three Months Ended March 31, 2019

Operating lease expense	$	208,912

Minimum rental payments under operating leases are recognized on a straight light basis over the term of the lease.

Maturity of operating leases

Schedule of Future Minimum Lease Payments

The amount of future minimum lease payments under operating are as follows:

	Operating Lease

Undiscounted future minimum lease payments:
2019 (remainder of year)	$	637,733
2020		794,101
2021		643,082
2022		641,947
2023		611,158
Thereafter		1,100,783
Total		4,428,803
Amount representing imputed interest		(393,813	)
Total operating lease liability		4,034,990
Current portion of operating lease liability		(724,587	)
Operating lease liability, non-current	$	3,310,403

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Schedule of Notes Payable

	March 31, 2019			December 31, 2018

Note payable to The Edward S. Bredniak Trust in the amount of up to $2,000,000. An existing note payable with this entity in the amount of $379,676 has been combined into the new note payable. The note carries an interest rate of 10% per annum and all outstanding balances are due and payable December 31, 2019.	$	1,684,426		$	1,584,426

Note payable to a financial institution in the amount of $200,000 dated November 15, 2017. The note requires 66 consecutive monthly installments of $2,652 including principal and interest at 5%, with a balloon payment of $60,000 which was paid on June 15, 2018. The note matures on May 15, 2023, and is secured by the personal guarantees of the Company’s management.		119,259			125,670

Convertible notes issued to various investors, which accrued interest at 4%, and converted to common stock in connection with the closing of the Company’s initial public offering. See Note 13. The notes were convertible to equity at or prior to maturity at a 20% discount to the per share price of a sale of equity securities. At the time of issuance of the convertible notes, the Company was unable to calculate the amount of a beneficial conversion (“BCF”) and related discount to be recorded until the occurrence of a qualified financing by the Company. Upon the closing of the Company’s initial public offering, the Company recognized the BCF and related interest charge associated with the discount, and the BCF has been classified as a liability to the extent it met the conditions for derivative treatment at the time of recognition.		-			1,540,000

$1.2 million mortgage loan with a financial institution. The loan agreement is for 6-months and carries an interest rate 3.35%. The loan matured in 2018 and was extended to 2019. It is currently interest only and is now on a month to month basis.		1,232,500			1,232,500

Note payable to a financial institution in the amount of $131,400 dated August 1, 2016. The note requires 120 monthly installments of $1,394 including principal and interest at 5%. The note matures on July 1, 2026 and is secured by a letter of credit.		102,498			105,374

Note payable to a financial institution in the amount of $200,000 dated May 4, 2016. The note requires 60 monthly installments of $3,881 including principal and interest at 4.25%. The note matures on May 4, 2021 and is secured by the equipment and personal guarantees of the Company’s management.		96,232			106,778

Note payable to an employee in the amount of $101,906 dated March 8, 2017. The note requires 5 annual installments of $23,350 including principal and interest at 5%. The note matures on December 31, 2021 and is unsecured.		60,000			60,000

Note payable to a financial institution in the amount of $133,555 dated September 17, 2014. The note requires 60 monthly installments of $2,475 including principal and interest at 4.25%. The note matures on September 17, 2019.		14,625			21,845
		3,309,540			4,776,593
Less: current portion:		(3,032,686	)		(4,459,302	)
	$	276,854		$	317,291

Schedule of Principal Maturities of Notes Payable

Principal maturities of the Company’s notes payable are as follows:

Years Ending December 31,	Amount

2019 (nine months)	$	3,012,357
2020		104,435
2021		80,968
2022		43,935
2023		27,404
Thereafter		40,441
Total	$	3,309,540

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Aug. 31, 2018
Cash equivalents
Impairments of long lived assets
Advertising and marketing expense	$ 347,016	$ 93,178
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Percentage of voting interest acquired				100.00%
BioFirma LLC [Member]
Percentage of voting interest acquired				70.00%

Capital Requirements, Liquidity and Going Concern Considerations (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Working capital		$ 2,400,000		$ 13,100,000
Net loss		(1,599,187)	$ (404,664)
Net cash (used in) operating activities		(894,149)	(576,541)
Proceeds from initial public offering, net of related fees	$ 4,356,815	3,839,482
Extinguished liabilities		$ 7,200,000
Common Stock [Member]
Common stock issued for initial public offering		850,000
Proceeds from initial public offering, net of related fees		$ 4,300,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Concentration of Credit Risks - Schedule of Concentration Risk (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue [Member]
Concentration of credit risk, percentage	100.00%	100.00%
Revenue [Member] \| Patient Payment [Member]
Concentration of credit risk, percentage	54.00%	64.00%
Revenue [Member] \| Medicare Payment [Member]
Concentration of credit risk, percentage	22.00%	13.00%
Revenue [Member] \| Insurance Payment [Member]
Concentration of credit risk, percentage	24.00%	23.00%
Accounts Receivable [Member]
Concentration of credit risk, percentage	100.00%	100.00%
Accounts Receivable [Member] \| Patient Payment [Member]
Concentration of credit risk, percentage	54.00%	64.00%
Accounts Receivable [Member] \| Medicare Payment [Member]
Concentration of credit risk, percentage	22.00%	13.00%
Accounts Receivable [Member] \| Insurance Payment [Member]
Concentration of credit risk, percentage	24.00%	23.00%

Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
Gross accounts receivable	$ 727,976	$ 314,185
Less: allowance for doubtful accounts and contractual adjustments	(62,896)	(10,555)
Accounts receivable, net	$ 665,080	$ 303,630

Business Acquisitions (Details Narrative) - USD ($)				6 Months Ended
Business Acquisitions (Details Narrative) - USD ($)	Aug. 31, 2018	Aug. 01, 2018	Jun. 01, 2018	Jun. 30, 2018	Mar. 31, 2019
CMA of Kentucky and IMAC St. Louis [Member]
Business acquisition, consideration amount				$ 6,100,000
IMAC Nashville [Member]
Business acquisition, consideration amount			$ 300,000
Business acquisition, non-controlling interest				$ 300,000
Membership interest percentage			25.00%
Advantage Therapy and BioFirma [Member]
Consideration amount payable in cash	$ 900,000
IMAC of St. Louis, LLC [Member]
Business acquisition, consideration amount			$ 1,490,632
Membership interest percentage			64.00%
Ownership percentage			100.00%
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Business acquisition, non-controlling interest
Membership interest percentage	100.00%
Estimated purchase price of membership units		$ 892,000
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member] \| Cash [Member]
Estimated purchase price of membership units		22,000
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member] \| Equity [Member]
Estimated purchase price of membership units		$ 870,000
BioFirma LLC [Member]
Business acquisition, non-controlling interest					$ 429
Membership interest percentage	70.00%
Percentage of outstanding membership units		70.00%
Payments to acquire business gross		$ 1,000

Business Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Goodwill	$ 2,042,125	$ 2,042,125
IMAC Kentucky [Member]
Property & equipment	607,257
Intangible Assets	4,224,113
Goodwill
Other assets	5,521
Current liabilities	(119,902)
Noncurrent liabilities	(118,413)
Non-controlling interest
Net Assets Acquired	4,598,576
IMAC St. Louis [Member]
Property & equipment
Intangible Assets	264,000
Goodwill	1,327,507
Other assets
Current liabilities
Noncurrent liabilities
Non-controlling interest
Net Assets Acquired	1,591,507
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Property & equipment	18,647
Intangible Assets	37,000
Goodwill	713,189
Other assets	255,018
Current liabilities	(50,948)
Noncurrent liabilities	(79,975)
Non-controlling interest
Net Assets Acquired	892,931
BioFirma LLC [Member]
Property & equipment
Intangible Assets	1,429
Goodwill
Other assets
Current liabilities
Noncurrent liabilities
Non-controlling interest	(429)
Net Assets Acquired	$ 1,000

Property and Equipment (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Depreciation		$ 154,881	$ 31,268
Lexington Kentucky [Member]
Payments to acquire real estate	$ 1,200,000

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Total property and equipment	$ 4,347,424	$ 3,782,921
Less: accumulated depreciation	(1,126,241)	(449,283)
Total property and equipment, net	$ 3,221,183	3,333,638
Land and Building [Member]
Estimated Useful Life in Years	40 years
Total property and equipment	$ 1,175,000	1,175,000
Leasehold Improvements [Member]
Estimated Useful Life	Shorter of asset or lease term
Total property and equipment	$ 1,614,778	1,427,828
Equipment [Member]
Total property and equipment	$ 1,557,646	$ 1,180,093
Equipment [Member] \| Minimum [Member]
Estimated Useful Life in Years	1 year 6 months
Equipment [Member] \| Maximum [Member]
Estimated Useful Life in Years	7 years

Intangibles Assets - Schedule of Intangible Assets (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Intangible assets, cost	$ 3,907,305	$ 4,525,113
Intangible assets, Accumulated Amortization	(398,365)	(267,679)
Intangible assets, net	4,126,748	4,257,434
Intangible assets, including goodwill, cost	6,567,238	6,567,238
Goodwill	2,042,125	2,042,125
Total intangible assets and goodwill	$ 6,168,873	$ 6,299,559
Definite Lived Assets [Member]
Intangible assets, estimated useful life	3 years	3 years
Intangible assets, cost	$ 4,525,113	$ 4,525,113
Intangible assets, Accumulated Amortization	(398,365)	(267,679)
Intangible assets, net	$ 4,126,748	$ 4,257,434
Management Service Agreement [Member]
Intangible assets, estimated useful life	10 years	10 years
Intangible assets, cost	$ 4,224,113	$ 4,224,113
Intangible assets, Accumulated Amortization	(316,808)	(211,206)
Intangible assets, net	3,907,305	4,012,907
Non Compete Agreement [Member]
Intangible assets, cost	301,000	301,000
Intangible assets, Accumulated Amortization	(81,557)	(56,473)
Intangible assets, net	$ 219,443	$ 244,527

Intangibles Assets - Schedule of Future Amortization of Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2019 (nine months)		$ 392,058
2020		522,744
2021		466,273
2022		422,411
2023		422,411
Thereafter		1,900,851
Total	$ 4,126,748	$ 4,257,434

Operating Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2019 (remainder of year)	$ 637,733
2020	794,101
2021	643,082
2022	641,947
2023	611,158
Thereafter	1,100,783
Total	4,428,803
Amount representing imputed interest	(393,813)
Total operating lease liability	4,034,990
Current portion of operating lease liability	(724,587)
Operating lease liability, non-current	$ 3,310,403

Lines of Credit (Details Narrative) - USD ($)	3 Months Ended
Lines of Credit (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Line of credit	$ 229,961	$ 379,961
IMAC Regeneration Center of Nashville, P.C [Member]
Line of credit	$ 150,000
Line of credit, maturity date	Oct. 15, 2018
Line of credit, interest rate	6.50%
Line of credit, repayment date	2019-02
IMAC Regeneration Center of Nashville, P.C [Member] \| Line of Credit [Member]
Line of credit	$ 150,000
IMAC Regeneration Center of Kentucky [Member]
Line of credit, maturity date	Aug. 01, 2018
Line of credit, interest rate	4.25%
IMAC Regeneration Center of Kentucky [Member] \| Line of Credit [Member]
Line of credit	$ 150,000	150,000
Advantage Theraphy [Member]
Line of credit	$ 100,000
Line of credit, maturity date	Nov. 20, 2020
Line of credit, interest rate	6.00%
Advantage Theraphy [Member] \| Line of Credit [Member]
Line of credit	$ 79,961	$ 79,975

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Notes payable	$ 3,309,540	$ 4,776,593
Less: current portion	(3,032,686)	(4,459,302)
Notes payable, net of current portion	276,854	317,291
Notes Payable [Member]
Notes payable	1,684,426	1,584,426
Notes Payable One [Member]
Notes payable	119,259	125,670
Notes Payable Two [Member]
Notes payable		1,540,000
Notes Payable Three [Member]
Notes payable	1,232,500	1,232,500
Notes Payable Four [Member]
Notes payable	102,498	105,374
Notes Payable Five [Member]
Notes payable	96,232	106,778
Notes Payable Six [Member]
Notes payable	60,000	60,000
Notes Payable Seven [Member]
Notes payable	$ 14,625	$ 21,845

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)	Jun. 01, 2018 USD ($)	Nov. 15, 2017 USD ($) Integer	Mar. 08, 2017 USD ($) Integer	Aug. 01, 2016 USD ($) Integer	May 04, 2016 USD ($) Integer	Sep. 17, 2014 USD ($) Integer	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Jun. 15, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jan. 31, 2018
Notes payable							$ 3,309,540	$ 4,776,593
Notes Payable [Member]
Debt instrument face amount	$ 2,000,000
Notes payable	$ 379,676
Debt instrument interest rate	10.00%
Debt instrument maturity date	Dec. 31, 2019
Notes Payable One [Member]
Notes payable		$ 200,000
Debt instrument interest rate		5.00%
Debt instrument maturity date		May 15, 2023
Number of installments \| Integer		66
Debt instrument, periodic payment		$ 2,652
Debt instrument balloon payment									$ 60,000
Notes Payable Two [Member]
Debt instrument interest rate											4.00%
Debt instrument discount, percentage											20.00%
Notes Payable Three [Member]
Debt instrument face amount										$ 1,200,000
Debt instrument interest rate										3.35%
Notes Payable Four [Member]
Notes payable				$ 131,400
Debt instrument interest rate				5.00%
Debt instrument maturity date				Jul. 01, 2026
Number of installments \| Integer				120
Debt instrument, periodic payment				$ 1,394
Notes Payable Five [Member]
Notes payable					$ 200,000
Debt instrument interest rate					4.25%
Debt instrument maturity date					May 04, 2021
Number of installments \| Integer					60
Debt instrument, periodic payment					$ 3,881
Notes Payable Six [Member]
Notes payable			$ 101,906
Debt instrument interest rate			5.00%
Debt instrument maturity date			Dec. 31, 2021
Number of installments \| Integer			5
Debt instrument, periodic payment			$ 23,350
Notes Payable Seven [Member]
Notes payable						$ 133,555
Debt instrument interest rate						4.25%
Debt instrument maturity date						Sep. 17, 2019
Number of installments \| Integer						60
Debt instrument, periodic payment						$ 2,475

Notes Payable - Schedule of Principal Maturities of Notes Payable (Details)	Dec. 31, 2018 USD ($)
Debt Disclosure [Abstract]
2019 (nine months)	$ 3,012,357
2020	104,435
2021	80,968
2022	43,935
2023	27,404
Thereafter	40,441
Total	$ 3,309,540

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2018	Mar. 31, 2019	Dec. 31, 2018
Due to related party
SpeakLife [Member]
Services fee	$ 99,000
UCI [Member]
Services fee	$ 144,000

Shareholders' Equity (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Feb. 12, 2019	Jun. 01, 2018	Feb. 28, 2019	Mar. 31, 2019	Mar. 31, 2018
Number of units authorized				400
Number of units issued				365
Number of units outstanding				365
Conversion of units into shares, shares		6,582,737
Shares issued price per share		$ 0.001
Reverse split of common stock outstanding	4,533,623
Gross proceeds from initial public offering			$ 4,356,815	$ 3,839,482
2018 Business Acquisitions [Member]
Stock issued during period, acquisitions			1,410,183
4% Convertible Notes [Member]
Stock issued during period, conversion of securities			449,217
Debt instrument, interest rate			4.00%
Common Stock [Member]
Number of shares issued during period, shares				850,000
Gross proceeds from initial public offering				$ 4,300,000
Stock issued during period, conversion of securities				449,217
Stock issued during period, acquisitions				1,410,183
Initial Public Offering [Member] \| Common Stock [Member]
Number of shares issued during period, shares			850,000
Initial Public Offering [Member] \| Warrants to Purchase Common Stock [Member]
Number of shares issued during period, shares			1,700,000
Initial Public Offering [Member] \| Stock Options [Member]
Number of shares issued during period, shares			34,000

Retirement Plan (Details Narrative) - 401(k) Plan [Member] - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Matching contributions, percentage of match	50.00%	50.00%
Matching contributions, percent of employees' gross pay	6.00%	6.00%
Matching contributions, amount	$ 7,407	$ 0

Income Taxes (Details Narrative)	3 Months Ended
Income Taxes (Details Narrative)	Mar. 31, 2019 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforward, net	$ 3,700,000
Operating loss carryforward, description	If not used, this carryforward will begin to expire in 2029. The deferred tax asset relating to the operating loss carryforward has been fully reserved at March 31, 2019.

Income Taxes - Schedule of Statutory Federal Income Tax Rate (Details)	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Deferred tax benefit at the federal statutory rate	21.00%
Valuation allowance	(21.00%)
Statutory federal income tax rate

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Apr. 22, 2019	Apr. 19, 2019
Dr. Jason Hui [Member] \| March 31, 2020 [Member]
Subsequent Event [Line Items]
Base salary		$ 350,000
Dr. Jason Hui [Member] \| April 1, 2020 through March 31, 2021 [Member]
Subsequent Event [Line Items]
Base salary		355,000
Dr. Jason Hui [Member] \| April 1, 2021 through March 31, 2022 [Member]
Subsequent Event [Line Items]
Base salary		$ 360,000
Merger Agreement [Member] \| Restricted Stock [Member]
Subsequent Event [Line Items]
Stock issued during period, conversion of securities	1,002,306

Concentration of Credit Risks (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Risks and Uncertainties [Abstract]
FDIC insured amount	$ 250,000
Cash and cash equivalents in excess of FDIC	$ 2,536,458	$ 0

Operating Leases - Summary of Right of Use Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Right of use assets, net of amortization	$ 4,027,124